| 1. |
El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol, 2017, 119: 1-12.
|
| 2. |
中國抗癌協會整合腫瘤心臟病學分會, 中華醫學會心血管病學分會腫瘤心臟病學學組, 中國醫師協會心血管內科醫師分會腫瘤心臟病學專業委員會, 等. 免疫檢查點抑制劑相關心肌炎監測與管理中國專家共識(2020 版). 中國腫瘤臨床, 2021, 48(2): 92.
|
| 3. |
Ladak K, Bass AR. Checkpoint inhibitor-associated autoimmunity. Best Pract Res Clin Rheumatol, 2018, 32(6): 781-802.
|
| 4. |
Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev, 2019, 40(1): 17-65.
|
| 5. |
Verspohl SH, Holderried T, Behning C, et al. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis, 2021, 13: 1759720x211006963.
|
| 6. |
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(2): 173-182.
|
| 7. |
Byrne MM, Lucas M, Pai L, et al. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors. Eur J Haematol, 2021, 107(6): 650-657.
|
| 8. |
Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev, 2017, 58: 70-76.
|
| 9. |
Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 2015, 35(1): 76-83.
|
| 10. |
Zheng Z, Liu Y, Yang J, et al. Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes Metab Res Rev, 2021, 37(1): e3366.
|
| 11. |
Iglesias P, Peiró I, Biagetti B, et al. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Endocr Relat Cancer, 2021, 28(12): 783-792.
|
| 12. |
Owen CN, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol, 2021, 32(7): 917-925.
|
| 13. |
Griewing LM, Schweizer C, Schubert P, et al. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer, 2021, 21(1): 314.
|
| 14. |
Marschner D, Falk M, Javorniczky NR, et al. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI insight, 2020, 5(6): e132334.
|
| 15. |
Hribernik N, Huff DT, Studen A, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging, 2022, 49(6): 1857-1869.
|
| 16. |
Abed A, Law N, Calapre L, et al. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. Eur J Cancer, 2022, 172: 98-106.
|
| 17. |
Luo J, Martucci VL, Quandt Z, et al. Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer. Clin Cancer Res, 2021, 27(108): 5131-5140.
|
| 18. |
Takeno A, Yamamoto M, Morita M, et al. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. BMC Endocr Disord, 2019, 19(1): 25.
|
| 19. |
Antoniou S, Bazazo G, R?ckl L, et al. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report. BMC Endocr Disord, 2021, 21(1): 191.
|
| 20. |
Teramoto Y, Nakamura Y, Asami Y, et al. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol, 2017, 44(5): 605-606.
|
| 21. |
Kundert P, Siatecka H, Suliburk J, et al. Unexpected persistently increased intraoperative parathyroid hormone concentrations in a patient with primary hyperparathyroidism. Clin Chem, 2021, 67(9): 1182-1186.
|
